AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

NCT00819221 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: AZD2281
DRUG: liposomal doxorubicin

Sponsor

AstraZeneca